166663-25-8 | Anidulafungin

Packsize	Purity	Availability	Price	Discounted Price
1mg	≥95%	in stock	$42.00	$29.00
5mg	≥95%	in stock	$141.00	$99.00
10mg	≥95%	in stock	$237.00	$166.00
25mg	≥98%	in stock	$311.00	$218.00
50mg	≥95%	in stock	$439.00	$307.00
100mg	≥98%	in stock	$634.00	$444.00
250mg	≥98%	in stock	$1,227.00	$859.00

Description

• Catalog Number: AA89071
• Chemical Name: Anidulafungin
• CAS Number: 166663-25-8
• Molecular Formula: C58H73N7O17
• Molecular Weight: 1140.2369
• MDL Number: MFCD00917070
• SMILES: CCCCCOc1ccc(cc1)c1ccc(cc1)c1ccc(cc1)C(=O)NC1CC(O)C(O)NC(=O)C2C(O)C(CN2C(=O)C(NC(=O)C(NC(=O)C2N(C(=O)C(NC1=O)C(O)C)CC(C2)O)C(C(c1ccc(cc1)O)O)O)C(O)C)C

Computed Properties

• Complexity: 2150
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 15
• Heavy Atom Count: 82
• Hydrogen Bond Acceptor Count: 17
• Hydrogen Bond Donor Count: 14
• Rotatable Bond Count: 14
• XLogP3: 2.3

Literature

• Activities of fluconazole, caspofungin, anidulafungin, and amphotericin B on planktonic and biofilm Candida species determined by microcalorimetry.

  Antimicrobial agents and chemotherapy 20140501

• In vitro effectiveness of anidulafungin against Candida sp. biofilms.

  The Journal of antibiotics 20131201

• Comparative in vitro fungicidal activity of echinocandins against Candida albicans in peritoneal dialysis fluids.

  Mycoses 20131101

• Epidemiology and echinocandin susceptibility of Candida parapsilosis sensu lato species isolated from bloodstream infections at a Spanish university hospital.

  The Journal of antimicrobial chemotherapy 20121101

• Identification and characterization of the echinocandin B biosynthetic gene cluster from Emericella rugulosa NRRL 11440.

  Journal of the American Chemical Society 20121010

• Molecular characterization and antifungal susceptibility of the Candida parapsilosis species complex of clinical isolates from Monterrey, Mexico.

  Medical mycology 20121001

• Anidulafungin--challenges in development and validation of an LC-MS/MS bioanalytical method validated for regulated clinical studies.

  Analytical and bioanalytical chemistry 20121001

• Successful medical management of recalcitrant Fusarium solani keratitis: molecular identification and susceptibility patterns.

  Mycopathologia 20120901

• In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis.

  The Journal of antimicrobial chemotherapy 20120901

• Anidulafungin--a new therapeutic option for Candida infections in liver transplantation.

  Transplantation proceedings 20120901

• Flash pulmonary oedema during anidulafungin administration.

  Journal of clinical pharmacy and therapeutics 20120801

• In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs.

  The Journal of antimicrobial chemotherapy 20120801

• (1,3)-β-D-glucan as a prognostic marker of treatment response in invasive candidiasis.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120801

• Isothermal microcalorimetry for antifungal susceptibility testing of Mucorales, Fusarium spp., and Scedosporium spp.

  Diagnostic microbiology and infectious disease 20120801

• Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values.

  Diagnostic microbiology and infectious disease 20120801

• Elaboration of antibiofilm surfaces functionalized with antifungal-cyclodextrin inclusion complexes.

  FEMS immunology and medical microbiology 20120701

• Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients.

  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20120701

• Isothermal microcalorimetry: a novel method for real-time determination of antifungal susceptibility of Aspergillus species.

  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20120701

• In vitro synergy testing of anidulafungin with fluconazole, tioconazole, 5-flucytosine and amphotericin B against some Candida spp.

  Medicinal chemistry (Shariqah (United Arab Emirates)) 20120701

• Some chronic rhinosinusitis patients have elevated populations of fungi in their sinuses.

  The Laryngoscope 20120701

• EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST).

  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20120701

• Comparison of the Etest and a rapid flow cytometry-based method with the reference CLSI broth microdilution protocol M27-A3 for the echinocandin susceptibility testing of Candida spp.

  European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 20120601

• Quantitative analysis of the antifungal drug anidulafungin by LC-online SPE-MS/MS in human plasma.

  Biomedical chromatography : BMC 20120601

• Safety of anidulafungin in solid organ transplant recipients.

  Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 20120601

• Non-clinical safety assessment and toxicokinetics of voriconazole and anidulafungin in the juvenile rat: a combination study design in support of a Paediatric Investigation Plan.

  Regulatory toxicology and pharmacology : RTP 20120601

• In vitro efficacy of the combination of voriconazole and anidulafungin against voriconazole-resistant cyp51A mutants of Aspergillus fumigatus.

  Diagnostic microbiology and infectious disease 20120601

• Convergent Evolution of Calcineurin Pathway Roles in Thermotolerance and Virulence in Candida glabrata.

  G3 (Bethesda, Md.) 20120601

• Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study.

  Mycoses 20120501

• Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey.

  The Journal of antimicrobial chemotherapy 20120501

• Evaluation of disk diffusion method compared to broth microdilution for antifungal susceptibility testing of 3 echinocandins against Aspergillus spp.

  Diagnostic microbiology and infectious disease 20120501

• The activity of echinocandins, amphotericin B and voriconazole against fluconazole-susceptible and fluconazole-resistant Brazilian Candida glabrata isolates.

  Memorias do Instituto Oswaldo Cruz 20120501

• [New apects in the diagnosis and therapy of dermatomycoses].

  Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 20120501

• The role of micafungin and anidulafungin in the treatment of systemic fungal infections: applications and patents for two novel echinocandins.

  Recent patents on anti-infective drug discovery 20120401

• Combined therapy of voriconazole and anidulafungin in murine infections by Aspergillus flavus.

  Mycopathologia 20120401

• Comparison between a high-resolution single-stage Orbitrap and a triple quadrupole mass spectrometer for quantitative analyses of drugs.

  Rapid communications in mass spectrometry : RCM 20120315

• Influence of serum on in vitro susceptibility testing of echinocandins for Candida parapsilosis and Candida guilliermondii.

  Mycoses 20120301

• Effect of protein binding on the activity of voriconazole alone or combined with anidulafungin against Aspergillus spp. using a time-kill methodology.

  Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia 20120301

• Systematic review of safety in paediatric drug trials published in 2007.

  European journal of clinical pharmacology 20120201

• Multiple subcutaneous cysts due to Exophiala spinifera in an immunocompetent patient.

  Medical mycology 20120201

• Comparison of anidulafungin's and fluconazole's in vivo activity in neutropenic and non-neutropenic models of invasive candidiasis.

  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20120201

• Epidemiology, risk factors and therapy of candidemia in pediatric hematological patients.

  Pediatric reports 20120102

• Poor compliance with antifungal drug use guidelines by transplant physicians: a framework for educational guidelines and an international consensus on patient safety.

  Clinical transplantation 20120101

• Anidulafungin: when and how? The clinician's view.

  Mycoses 20120101

• Protein Glycosylation in Aspergillus fumigatus Is Essential for Cell Wall Synthesis and Serves as a Promising Model of Multicellular Eukaryotic Development.

  International journal of microbiology 20120101

• Development of a 96-well catheter-based microdilution method to test antifungal susceptibility of Candida biofilms.

  The Journal of antimicrobial chemotherapy 20120101

• [Cost analysis of 3 candins in the treatment of invasive candidiasis in adult non-neutropaenic patients in Spain].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20120101

• Candida biofilms and the host: models and new concepts for eradication.

  International journal of microbiology 20120101

• Antifungal resistance and new strategies to control fungal infections.

  International journal of microbiology 20120101

• Echinocandin use in the neonatal intensive care unit.

  The Annals of pharmacotherapy 20120101

• Candida spp. with acquired echinocandin resistance, France, 2004-2010.

  Emerging infectious diseases 20120101

• Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients.

  Infection and drug resistance 20120101

• Outcome of Antifungal Combination Therapy for Invasive Mold Infections in Hematological Patients is Independent of the Chosen Combination.

  Mediterranean journal of hematology and infectious diseases 20120101

• Chemosensitization as a means to augment commercial antifungal agents.

  Frontiers in microbiology 20120101

• Therapeutic use of a cationic antimicrobial peptide from the spider Acanthoscurria gomesiana in the control of experimental candidiasis.

  BMC microbiology 20120101

• Rapid susceptibility testing and microcolony analysis of Candida spp. cultured and imaged on porous aluminum oxide.

  PloS one 20120101

• [Persistent candidemia in a renal-pancreatic transplant patient].

  Revista iberoamericana de micologia 20120101

• [Candida peritonitis in a haemodynamically stable patient. First choice of antifungal treatment … fluconazole?].

  Revista iberoamericana de micologia 20120101

• [Echinocandins in a critically ill patient during continuous venovenous renal replacement].

  Revista iberoamericana de micologia 20120101

• [Invasive candidiasis in a lung retransplantation recipient].

  Revista iberoamericana de micologia 20120101

• Risk factors and outcomes of candidemia caused by biofilm-forming isolates in a tertiary care hospital.

  PloS one 20120101

• Comparison of human and soil Candida tropicalis isolates with reduced susceptibility to fluconazole.

  PloS one 20120101

• Microcolony imaging of Aspergillus fumigatus treated with echinocandins reveals both fungistatic and fungicidal activities.

  PloS one 20120101

• Effects of anidulafungin and voriconazole, singly and in combination, on cytokine/chemokine production by human monocyte-derived macrophages infected with Candida glabrata or activated by lipopolysaccharide.

  Chemotherapy 20120101

• Pharmacological assessment of the medicinal potential of Acacia mearnsii De Wild.: antimicrobial and toxicity activities.

  International journal of molecular sciences 20120101

• Inhibition of ion channels and heart beat in Drosophila by selective COX-2 inhibitor SC-791.

  PloS one 20120101

• β-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study.

  PloS one 20120101

• Advances in systemic antifungal therapy.

  Clinics in dermatology 20120101

• In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.

  Diagnostic microbiology and infectious disease 20111201

• Current role of echinocandins in the management of invasive aspergillosis.

  Current infectious disease reports 20111201

• Efg1 Controls caspofungin-induced cell aggregation of Candida albicans through the adhesin Als1.

  Eukaryotic cell 20111201

• Invasive candidiasis following liver transplantation and surgical complications.

  Mycoses 20111201

• Anidulafungin treatment in a kidney transplant recipient with hepatic damage.

  Mycoses 20111201

• Recurrent candidaemia and pacemaker wire infection with Candida albicans.

  Mycoses 20111201

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• [Echinocandins].

  Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia 20111201

• [Antifungal therapy update: new drugs and medical uses].

  Enfermedades infecciosas y microbiologia clinica 20111201

• Characterization of Candida parapsilosis complex strains isolated from invasive fungal infections.

  European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 20111101

• Microdilution in vitro antifungal susceptibility of Exophiala dermatitidis, a systemic opportunist.

  Medical mycology 20111101

• Efficacy of anidulafungin against biofilms of different Candida species in long-term trials of continuous flow cultivation.

  Mycoses 20111101

• In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods.

  Antimicrobial agents and chemotherapy 20111101

• EUCAST technical note on anidulafungin.

  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20111101

• Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antifungal, antitubercular and miscellaneous anti-infective agents.

  Clinical pharmacokinetics 20111101

• New β-glucan inhibitors as antifungal drugs.

  Expert opinion on therapeutic patents 20111001

• Prevalence and antifungal susceptibility patterns of new cryptic species inside the species complexes Candida parapsilosis and Candida glabrata among blood isolates from a Spanish tertiary hospital.

  The Journal of antimicrobial chemotherapy 20111001

• Efficacy of anidulafungin against Aspergillus niger in vitro and in vivo.

  International journal of antimicrobial agents 20111001

• Post-antifungal effects and time-kill studies of anidulafungin, caspofungin, and micafungin against Candida glabrata and Candida parapsilosis.

  Diagnostic microbiology and infectious disease 20111001

• Austrian clinical practice with anidulafungin in 2008: a multicenter survey.

  Journal of chemotherapy (Florence, Italy) 20111001

• Breakthrough fungemia due to Candida glabrata during posaconazole prophylaxis in hematology patients treated with anidulafungin - report of 5 cases.

  Journal of chemotherapy (Florence, Italy) 20111001

• [In vitro andulafungin susceptibility of 100 of Candida strains obtained previously to the introduction of this echinocandin in Chile].

  Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia 20111001

• Fluconazole-, amphotericin-B-, caspofungin-, and anidulafungin-resistant Candida ciferrii: an unknown cause of systemic mycosis in a child.

  Mycopathologia 20110901

• In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs.

  Mycoses 20110901

• Detailed comparison of Candida albicans and Candida glabrata biofilms under different conditions and their susceptibility to caspofungin and anidulafungin.

  Journal of medical microbiology 20110901

• Posaconazole: a new antifungal weapon.

  Reviews on recent clinical trials 20110901

• Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients.

  PharmacoEconomics 20110801

• Juvenile toxicity assessment of anidulafungin in rats: an example of navigating case-by-case study design through scientific and regulatory challenges.

  Birth defects research. Part B, Developmental and reproductive toxicology 20110801

• Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis.

  The Journal of antimicrobial chemotherapy 20110801

• Determination of micafungin and anidulafungin in human plasma: UV- or mass spectrometric quantification?

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110715

• Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009).

  International journal of antimicrobial agents 20110701

• Echinocandins: addressing outstanding questions surrounding treatment of invasive fungal infections.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110701

• Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.

  Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20110601

• Comparative in vivo dose-dependent activity of caspofungin and anidulafungin against echinocandin-susceptible and -resistant Aspergillus fumigatus.

  The Journal of antimicrobial chemotherapy 20110601

• Are anidulafungin or voriconazole released from polymethylmethacrylate in vitro?

  Clinical orthopaedics and related research 20110501

• Isolation of Cryptococcus magnus and Cryptococcus chernovii from nasal cavities of pediatric patients with acute lymphoblastic leukemia.

  Medical mycology 20110501

• Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates.

  Clinical pharmacology and therapeutics 20110501

• Development of an HPLC method for the determination of anidulafungin in human plasma and saline.

  Journal of chromatographic science 20110501

• [Echinocandins in children].

  Archives de pediatrie : organe officiel de la Societe francaise de pediatrie 20110501

• The value of amphotericin B in the treatment of invasive fungal infections.

  Journal of critical care 20110401

• In vitro interactions among echinocandins against Aspergillus fumigatus: lack of concordance among methods.

  Medical mycology 20110401

• Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis.

  Antimicrobial agents and chemotherapy 20110401

• Multiple-dose pharmacokinetics of anidulafungin during continuous venovenous haemofiltration.

  The Journal of antimicrobial chemotherapy 20110401

• Current perspectives on echinocandin class drugs.

  Future microbiology 20110401

• Antifungal susceptibility testing of a 10-year collection of Candida spp. isolated from patients with candidemia.

  Journal of chemotherapy (Florence, Italy) 20110401

• Comparative in vitro susceptibility of clinical isolates of Candida paparsilosis complex and other Candida species to caspofungin and anidulafungin by Etest.

  Journal of chemotherapy (Florence, Italy) 20110401

• Characterization of Candida parapsilosis complex isolates.

  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20110301

• Additive antifungal activity of anidulafungin and human neutrophils against Candida parapsilosis biofilms.

  The Journal of antimicrobial chemotherapy 20110301

• Anidulafungin for the treatment of invasive candidiasis.

  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20110301

• Anidulafungin: is it a promising option in the treatment of pediatric invasive fungal infections?

  Expert review of anti-infective therapy 20110301

• In vitro activity of echinocandins against non-Candida albicans: is echinocandin antifungal activity the same?

  Enfermedades infecciosas y microbiologia clinica 20110301

• [Drug interactions in critically-ill patients. An important factor in the use of micafungin?].

  Enfermedades infecciosas y microbiologia clinica 20110301

• Current evidence of antifungal prophylaxis and therapy in pediatric patients.

  Pediatric reports 20110224

• [Prevalence of Candida parapsilosis, C. orthopsilosis and C. metapsilosis in candidemia over a 5-year period at Nantes hospital and in vitro susceptibility to three echinocandins by E-test®].

  Pathologie-biologie 20110201

• Echinocandin antifungal drugs in fungal infections: a comparison.

  Drugs 20110101

• Fusarium infection in lung transplant patients: report of 6 cases and review of the literature.

  Medicine 20110101

• Comparative genomics allowed the identification of drug targets against human fungal pathogens.

  BMC genomics 20110101

• Penicillium marneffei Infection in AIDS.

  Pathology research international 20110101

• Economic considerations of antifungal prophylaxis in patients undergoing surgical procedures.

  Therapeutics and clinical risk management 20110101

• A Comprehensive review of abdominal infections.

  World journal of emergency surgery : WJES 20110101

• Treatment of candidemia in adult patients without neutropenia--an inconvenient truth.

  Critical care (London, England) 20110101

• Antifungal testing and high-throughput screening of compound library against Geomyces destructans, the etiologic agent of geomycosis (WNS) in bats.

  PloS one 20110101

• [Antifungal prophylaxis in HIV-seropositive liver transplant recipients].

  Revista iberoamericana de micologia 20110101

• Antimicrobial treatment of 'complicated' intra-abdominal infections and the new IDSA guidelines ? a commentary and an alternative European approach according to clinical definitions.

  European journal of medical research 20110101

• Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin: review of the literature.

  European journal of medical research 20110101

• Epidemiology and antifungal resistance in invasive Aspergillosis according to primary disease: review of the literature.

  European journal of medical research 20110101

• Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature.

  European journal of medical research 20110101

• Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature.

  European journal of medical research 20110101

• Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature.

  European journal of medical research 20110101

• Epidemiology and antifungal resistance in invasive candidiasis.

  European journal of medical research 20110101

• Pathogenesis and treatment of oral candidosis.

  Journal of oral microbiology 20110101

• Antifungal susceptibility of invasive yeast isolates in Italy: the GISIA3 study in critically ill patients.

  BMC infectious diseases 20110101

• Epidemiology of invasive fungal infections in the mediterranean area.

  Mediterranean journal of hematology and infectious diseases 20110101

• Invasive Candida infections in patients with haematological malignancies and hematopoietic stem cell transplant recipients: current epidemiology and therapeutic options.

  Mediterranean journal of hematology and infectious diseases 20110101

• Five-years surveillance of invasive aspergillosis in a university hospital.

  BMC infectious diseases 20110101

• Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole.

  Molecular systems biology 20110101

• [Invasive candidiasis in liver transplant recipient: early rescue antifungal treatment].

  Revista iberoamericana de micologia 20110101

• Post-transplant aspergillosis and the role of combined neurosurgical and antifungal therapies under belatacept immunosuppression.

  Surgical neurology international 20110101

• Epidemiology and treatment approaches in management of invasive fungal infections.

  Clinical epidemiology 20110101

• Emerging fungal infections in immunocompromised patients.

  F1000 medicine reports 20110101

• Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome.

  BMC infectious diseases 20110101

• Efficacy and safety of current drug therapies for invasive aspergillosis.

  Pharmacology 20110101

• Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis.

  Critical care (London, England) 20110101

• Candida colonization index in patients admitted to an ICU.

  International journal of molecular sciences 20110101

• Antimicrobial therapy for the treatment of opportunistic infections in HIV/AIDS patients: a critical appraisal.

  HIV/AIDS (Auckland, N.Z.) 20110101

• [Susceptibility to antifungal agents of Candida sp. and biofilm formation].

  Medycyna doswiadczalna i mikrobiologia 20110101

• Radioimmunotherapy of fungal diseases: the therapeutic potential of cytocidal radiation delivered by antibody targeting fungal cell surface antigens.

  Frontiers in microbiology 20110101

• Spontaneous esophageal perforation in a patient with mixed connective tissue disease.

  The open rheumatology journal 20110101

• Species distribution and susceptibility profile of yeasts isolated from blood cultures: results of a multicenter active laboratory-based surveillance study in Argentina.

  Revista Argentina de microbiologia 20110101

• Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin.

  Antimicrobial agents and chemotherapy 20101201

• Clinical experience of anidulafungin for the treatment of patients with documented candidemia.

  Journal of chemotherapy (Florence, Italy) 20101201

• Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009).

  Diagnostic microbiology and infectious disease 20101101

• Chronic airway colonization by Scedosporium apiospermum with a fatal outcome in a patient with cystic fibrosis.

  Medical mycology 20101101

• Recent advances in the treatment of mucormycosis.

  Current infectious disease reports 20101101

• Septic bilateral pulmonary candidiasis successfully treated with anidulafungin therapy in two patients with peritoneal carcinomatosis.

  The Journal of antimicrobial chemotherapy 20101001

• Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections.

  Expert opinion on drug metabolism & toxicology 20101001

• Role of echinocandins in the management of fungal infections in neonates.

  The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 20101001

• Screening for drug-resistant Candida yeasts with chromogenic agar.

  Medical mycology 20100901

• Evaluation of the Etest method for susceptibility testing of Aspergillus spp. and Fusarium spp. to three echinocandins.

  Medical mycology 20100901

• Rhinocladiella aquaspersa, proven agent of verrucous skin infection and a novel type of chromoblastomycosis.

  Medical mycology 20100801

• [Anidulafungin: a new therapeutic option in systemic candidiasis].

  Medecine et maladies infectieuses 20100801

• Efficacy of anidulafungin, caspofungin and fluconazole in the early phase of infection in a neutropenic murine invasive candidiasis model.

  International journal of antimicrobial agents 20100701

• Antifungal susceptibility profile of human-pathogenic species of Lichtheimia.

  Antimicrobial agents and chemotherapy 20100701

• Case report 4: Elderly patient with concomitant conditions.

  Mycoses 20100701

• Case report 5: Intensive care unit patient assessed using the Candida Score.

  Mycoses 20100701

• Case report 6: Candidaemia in a high risk liver transplant recipient.

  Mycoses 20100701

• Interactions between human phagocytes and Candida albicans biofilms alone and in combination with antifungal agents.

  The Journal of infectious diseases 20100615

• [Therapy of candidemia and invasive candidiasis according to guidelines].

  Mycoses 20100501

• Traditional and emerging antifungal therapies.

  Proceedings of the American Thoracic Society 20100501

• In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp.

  Antimicrobial agents and chemotherapy 20100401

• Combination of caspofungin or anidulafungin with antimicrobial peptides results in potent synergistic killing of Candida albicans and Candida glabrata in vitro.

  International journal of antimicrobial agents 20100401

• In vitro activity of nine antifungal agents against clinical isolates of Aspergillus calidoustus.

  Medical mycology 20100201

• Fungal echinocandin resistance.

  Fungal genetics and biology : FG & B 20100201

• Fungicidal activity of anidulafungin in serum from patients does not correlate to its susceptible breakpoint against Candida spp.

  The Journal of antimicrobial chemotherapy 20100201

• Reverse genetics in Candida albicans predicts ARF cycling is essential for drug resistance and virulence.

  PLoS pathogens 20100201

• Echinocandins: A ray of hope in antifungal drug therapy.

  Indian journal of pharmacology 20100201

• [Antifungal combination therapy in invasive fungal infections].

  La Revue de medecine interne 20100101

• Medical claims and current applications of the potent echinocandin antifungals.

  Recent patents on anti-infective drug discovery 20100101

• The echinocandins: three useful choices or three too many?

  International journal of antimicrobial agents 20100101

• A clinical review of echinocandins in pediatric patients.

  The Annals of pharmacotherapy 20100101

• Species distribution and susceptibility profile of Candida species in a Brazilian public tertiary hospital.

  BMC research notes 20100101

• Echinocandin treatment of pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection.

  PloS one 20100101

• A focus on intra-abdominal infections.

  World journal of emergency surgery : WJES 20100101

• Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence.

  PloS one 20100101

• A formal model for analyzing drug combination effects and its application in TNF-alpha-induced NFkappaB pathway.

  BMC systems biology 20100101

• Genotypic and phenotypic properties of Candida parapsilosis sensu strictu strains isolated from different geographic regions and body sites.

  BMC microbiology 20100101

• Bench-to-bedside review: therapeutic management of invasive candidiasis in the intensive care unit.

  Critical care (London, England) 20100101

• Fungal echinocandin resistance.

  F1000 biology reports 20100101

• A rare case of toxic epidermal necrolysis with unexpected Fever resulting from dengue virus.

  Case reports in dermatology 20100101

• Current strategies for the prevention and management of central line-associated bloodstream infections.

  Infection and drug resistance 20100101

• Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection.

  HIV/AIDS (Auckland, N.Z.) 20100101

• Treatment of invasive candidiasis with echinocandins.

  Mycoses 20091101

• Neonatal peritoneal candidiasis successfully treated with anidulafungin add-on therapy.

  The Annals of pharmacotherapy 20091101

• Echinocandins: the newest class of antifungals.

  The Annals of pharmacotherapy 20091001

• Delivery of antifungal agents using bioactive and nonbioactive bone cements.

  The Annals of pharmacotherapy 20091001

• New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.

  Expert review of anti-infective therapy 20091001

• Extended daily dialysis does not affect the pharmacokinetics of anidulafungin.

  International journal of antimicrobial agents 20090901

• Anidulafungin and voriconazole in invasive fungal disease: pharmacological data and their use in combination.

  Expert opinion on investigational drugs 20090901

• Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates.

  Antimicrobial agents and chemotherapy 20090801

• Echinocandins: pharmacokinetic and therapeutic issues.

  Current medical research and opinion 20090701

• Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin.

  PLoS pathogens 20090701

• Lost in translation: differences in antimicrobial indication approval policies between the United States and Europe.

  Clinical therapeutics 20090701

• Overview of antifungal agents.

  Clinics in chest medicine 20090601

• Rapid Hemodynamic Deterioration and Death due to Acute Severe Refractory Septic Shock.

  Journal of clinical medicine research 20090601

• The changing face of epidemiology of invasive fungal disease in Europe.

  Mycoses 20090501

• [In vitro antifungal activity of micafungin].

  Revista iberoamericana de micologia 20090331

• [Micafungin: experimental therapy of fungal infections in animal models].

  Revista iberoamericana de micologia 20090331

• Antifungal activity of anidulafungin, a product of Aspergillus nidulans, against Aspergillus nidulans.

  International journal of antimicrobial agents 20090301

• In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin.

  Antimicrobial agents and chemotherapy 20090301

• Newer antifungal agents for invasive fungal infections in patients with haematological malignancy.

  British journal of haematology 20090301

• Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit.

  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20090301

• Utilization and dosage pattern of echinocandins for treatment of fungal infections in US hospital practice.

  Current medical research and opinion 20090201

• Clinical indications for newer antifungal agents.

  Journal of hospital medicine 20090201

• Anidulafungin: new drug. Invasive candidiasis: just another echinocandin.

  Prescrire international 20090201

• Pharmacology and antifungal properties of anidulafungin, a new echinocandin.

  Pharmacotherapy 20090101

• Antifungal treatment for invasive Candida infections: a mixed treatment comparison meta-analysis.

  Annals of clinical microbiology and antimicrobials 20090101

• Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B.

  Critical care (London, England) 20090101

• Successful treatment of Candida parapsilosis and Pseudomonas aeruginosa infection using medical and surgical management in an injecting drug user with mitral and aortic valve endocarditis: a case report.

  Journal of medical case reports 20090101

• Recent advances in the management of invasive candidiasis: role of anidulafungin.

  Drugs 20090101

• Clinical aspects of invasive candidiasis: endocarditis and other localized infections.

  Drugs 20090101

• Invasive fungal infections: the challenge continues.

  Drugs 20090101

• Pharmacological properties of antifungal drugs with a focus on anidulafungin.

  Drugs 20090101

• Anidulafungin, a new echinocandin: in vitro activity.

  Drugs 20090101

• Anidulafungin, a new echinocandin: effectiveness and tolerability.

  Drugs 20090101

• Conclusions. Anidulafungin is a new echinocandin developed for more effective treatment of serious systemic fungal infections.

  Drugs 20090101

• Review of the pharmacology and clinical studies of micafungin.

  Drug design, development and therapy 20090101

• Anidulafungin and its role in candida infections.

  Infection and drug resistance 20090101

• Proposed quality control ranges for 2-microg anidulafungin disk diffusion testing and ability of the method to detect strains with elevated echinocandin MIC values.

  Diagnostic microbiology and infectious disease 20081201

• Anidulafungin: a novel echinocandin for candida infections.

  Future microbiology 20081201

• Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts?

  Therapeutics and clinical risk management 20081201

• Amphotericin B lipid complex: treatment of invasive fungal infections in patients refractory to or intolerant of amphotericin B deoxycholate.

  Therapeutics and clinical risk management 20081201

• [Current status of invasive fungal infections. New diagnostic techniques and antifungal agents].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [In vitro activity of anidulafungin. Comparison with the activity of other echinocandins].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Pharmacokinetics and pharmacodynamics: interactions and adverse effects. Comparison with other echinocandins].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Current treatment of candidemia. Role of anidulafungin].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Role of anidulafungin in solid organ transplant recipients].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Role of anidulafungin in critically ill patients].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Potential of anidulafungin in hematological patients].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Potential of anidulafungin in combined therapy].

  Enfermedades infecciosas y microbiologia clinica 20081201

• A sterol-regulatory element binding protein is required for cell polarity, hypoxia adaptation, azole drug resistance, and virulence in Aspergillus fumigatus.

  PLoS pathogens 20081101

• Management of invasive Candida infections in non-neutropenic critically ill patients: from prophylaxis to early therapy.

  International journal of antimicrobial agents 20081101

• Anidulafungin in the treatment of patients with invasive candidiasis.

  International journal of antimicrobial agents 20081101

• Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis.

  Diagnostic microbiology and infectious disease 20081001

• Significant differences in drug susceptibility among species in the Candida parapsilosis group.

  Diagnostic microbiology and infectious disease 20080901

• Anidulafungin: a drug evaluation of a new echinocandin.

  Expert opinion on pharmacotherapy 20080901

• Antifungal treatment strategies in high risk patients.

  Mycoses 20080901

• Treatment of invasive candidal infections: systematic review and meta-analysis.

  Mayo Clinic proceedings 20080901

• [What distinctions do Candida biofilms have to offer?].

  Mycoses 20080901

• In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.

  Antimicrobial agents and chemotherapy 20080801

• Update in infectious disease treatment.

  Cleveland Clinic journal of medicine 20080801

• Posaconazole in the management of refractory invasive fungal infections.

  Therapeutics and clinical risk management 20080801

• Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae.

  The Journal of infectious diseases 20080715

• A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis.

  Journal of acquired immune deficiency syndromes (1999) 20080701

• [Echinocandins in invasive candidiasis].

  Medizinische Klinik (Munich, Germany : 1983) 20080615

• [Anidulafungin in the invasive fungal infection: current topics].

  Revista iberoamericana de micologia 20080601

• [Anidulafungin: a new echinocandin for the treatment of mycosis].

  Revista iberoamericana de micologia 20080601

• [The fungal cell wall and the mechanism of action of anidulafungin].

  Revista iberoamericana de micologia 20080601

• [In vitro antifungal activity of anidulafungin].

  Revista iberoamericana de micologia 20080601

• [Anidulafungin: a new therapeutic approach in antifungal therapy. Pharmacology of anidulafungin].

  Revista iberoamericana de micologia 20080601

• Mechanisms of resistance to antifungal agents: yeasts and filamentous fungi.

  Revista iberoamericana de micologia 20080601

• [Therapeutic efficacy of anidulafungin for the treatment of oesophageal candidiasis, candidemia and invasive candidiasis].

  Revista iberoamericana de micologia 20080601

• [Anidulafungin: experimental therapy of fungal infections in animal models].

  Revista iberoamericana de micologia 20080601

• [Activity of anidulafungin against Candida biofilms].

  Revista iberoamericana de micologia 20080601

• [The role of anidulafungin therapy in solid organ transplant recipients].

  Revista iberoamericana de micologia 20080601

• [Anidulafungin].

  Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia 20080601

• [Recommendations of antifungal treatment in patients with low grade immunosuppression].

  Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia 20080601

• Liposomal amphotericin B: what is its role in 2008?

  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20080501

• Stimulation of chitin synthesis rescues Candida albicans from echinocandins.

  PLoS pathogens 20080401

• Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis.

  European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 20080201

• In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.

  Antimicrobial agents and chemotherapy 20080201

• Management of Candida infections in the adult intensive care unit.

  Expert opinion on pharmacotherapy 20080201

• Anidulafungin in the treatment of invasive fungal infections.

  Therapeutics and clinical risk management 20080201

• Advances in antifungal therapy.

  Annual review of medicine 20080101

• Early clinical experience with anidulafungin at a large tertiary care medical center.

  Pharmacotherapy 20080101

• Anidulafungin was noninferior to fluconazole for invasive candidiasis.

  ACP journal club 20080101

• Propofol lipidic infusion promotes resistance to antifungals by reducing drug input into the fungal cell.

  BMC microbiology 20080101

• Bench-to-bedside review: Candida infections in the intensive care unit.

  Critical care (London, England) 20080101

• Patients at high risk of invasive fungal infections: when and how to treat.

  Drugs 20080101

• Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections.

  Drugs 20080101

• Micafungin in the treatment of invasive candidiasis and invasive aspergillosis.

  Infection and drug resistance 20080101

• A review of clinical experience with newer antifungals in children.

  The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG 20080101

• [In vitro activity of amphotericin B and anidulafungin against Candida spp. biofilms].

  Revista iberoamericana de micologia 20071231

• A review of the new antifungals: posaconazole, micafungin, and anidulafungin.

  Journal of drugs in dermatology : JDD 20071201

• Update on the treatment of disseminated fusariosis: Focus on voriconazole.

  Therapeutics and clinical risk management 20071201

• Mould breakthrough in immunosuppressed adults receiving anidulafungin: a report of 2 cases.

  The Journal of infection 20071101

• Antifungal drug discovery, six new molecules patented after 10 years of feast: why do we need new patented drugs apart from new strategies?

  Recent patents on anti-infective drug discovery 20071101

• Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients.

  Intensive care medicine 20071001

• Anidulafungin and fluconazole for candidiasis.

  The New England journal of medicine 20070927

• Anidulafungin and fluconazole for candidiasis.

  The New England journal of medicine 20070927

• Susceptibility patterns of Candida species recovered from Canadian intensive care units.

  Journal of critical care 20070901

• Recent advances in antifungal agents.

  Mini reviews in medicinal chemistry 20070901

• One year prospective survey of Candida bloodstream infections in Scotland.

  Journal of medical microbiology 20070801

• Role of posaconazole in the management of oropharyngeal and esophageal candidiasis.

  Therapeutics and clinical risk management 20070801

• Development of anidulafungin for disk diffusion susceptibility testing against Candida spp.

  Diagnostic microbiology and infectious disease 20070701

• Nongastroesophageal reflux disease-related infectious, inflammatory and injurious disorders of the esophagus.

  Current opinion in gastroenterology 20070701

• A comparative evaluation of properties and clinical efficacy of the echinocandins.

  Expert opinion on pharmacotherapy 20070701

• Anidulafungin versus fluconazole for invasive candidiasis.

  The New England journal of medicine 20070614

• Echinocandins--first-choice or first-line therapy for invasive candidiasis?

  The New England journal of medicine 20070614

• Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment.

  Journal of clinical pharmacology 20070401

• The echinocandins.

  Pharmacotherapy 20070301

• Lack of pharmacokinetic interaction between anidulafungin and tacrolimus.

  Journal of clinical pharmacology 20070301

• Essential gene identification and drug target prioritization in Aspergillus fumigatus.

  PLoS pathogens 20070301

• Comparison of echinocandin antifungals.

  Therapeutics and clinical risk management 20070301

• Anidulafungin: a new echinocandin for candidal infections.

  Expert review of anti-infective therapy 20070201

• New drugs 07, part I.

  Nursing 20070201

• Fungal infections of the CNS: treatment strategies for the immunocompromised patient.

  CNS drugs 20070101

• Anidulafungin--state of affairs from a clinical perspective.

  Mycoses 20070101

• Role of micafungin in the antifungal armamentarium.

  Current medicinal chemistry 20070101

• Antifungal agents in neonates: issues and recommendations.

  Paediatric drugs 20070101

• Update on new antifungal therapy.

  AACN advanced critical care 20070101

• Anidulafungin: an evidence-based review of its use in invasive fungal infections.

  Core evidence 20070101

• The safety of anidulafungin.

  Expert opinion on drug safety 20061101

• Echinocandins in the management of invasive fungal infections, Part 2.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20061001

• Echinocandins in the management of invasive fungal infections, part 1.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20060915

• Echinocandins for candidemia in adults without neutropenia.

  The New England journal of medicine 20060914

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20060901

• Anidulafungin: a new echinocandin for the treatment of fungal infections.

  Drugs of today (Barcelona, Spain : 1998) 20060801

• Anidulafungin: a novel echinocandin.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060715

• Voriconazole in the management of nosocomial invasive fungal infections.

  Therapeutics and clinical risk management 20060601

• Anidulafungin (Eraxis) for Candida infections.

  The Medical letter on drugs and therapeutics 20060522

• Emerging echinocandins for treatment of invasive fungal infections.

  Expert opinion on emerging drugs 20060501

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20060501

• Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis.

  The Journal of antimicrobial chemotherapy 20060401

• Echinocandin antifungals: review and update.

  Expert review of anti-infective therapy 20060401

• In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species.

  International journal of antimicrobial agents 20060201

• New drugs: lubiprostone, ranolazine, and anidulafungin.

  Journal of the American Pharmacists Association : JAPhA 20060101

• Another option for fungal infections.

  FDA consumer 20060101

• The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.

  Pharmacology 20060101

• Safety and pharmacokinetics of coadministered voriconazole and anidulafungin.

  Journal of clinical pharmacology 20051201

• Advances in antifungal therapy.

  The Pediatric infectious disease journal 20051001

• Management of systemic fungal infections: alternatives to itraconazole.

  The Journal of antimicrobial chemotherapy 20050901

• Acquisitions not a cure for anti-infectives.

  Nature reviews. Drug discovery 20050901

• Echinocandins: role in antifungal therapy, 2005.

  Expert opinion on pharmacotherapy 20050801

• Antifungal agents in children.

  Pediatric clinics of North America 20050601

• Anidulafungin: a new echinocandin with a novel profile.

  Clinical therapeutics 20050601

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20050501

• Overview of transplant mycology.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20050415

• Compatibility of anidulafungin with other drugs during simulated Y-site administration.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20050415

• Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine.

  Journal of clinical pharmacology 20050201

• New antifungal drugs and the pediatric cancer patient: current status of clinical development.

  Klinische Padiatrie 20050101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20050101

• Initial results from a longitudinal international surveillance programme for anidulafungin (2003).

  The Journal of antimicrobial chemotherapy 20041201

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20041201

• Pharmacokinetics/pharmacodynamics of echinocandins.

  European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 20041101

• Management of invasive mycoses in hematology patients: current approaches.

  Oncology (Williston Park, N.Y.) 20041101

• A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040915

• Echinocandins: ask not what they can do for esophageal candidiasis--ask what studies of esophageal candidiasis can do for them.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040915

• Effects of caspofungin (MK-0991) and anidulafungin (LY303366) on phagocytosis, oxidative burst and killing of Candida albicans by human phagocytes.

  European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 20040901

• Anidulafungin: an echinocandin antifungal.

  Expert opinion on investigational drugs 20040901

• Anidulafungin: review of a new echinocandin antifungal agent.

  Expert review of anti-infective therapy 20040801

• Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal.

  Journal of clinical pharmacology 20040601

• Fungal biofilms and drug resistance.

  Emerging infectious diseases 20040101

• Newer systemic antifungal agents : pharmacokinetics, safety and efficacy.

  Drugs 20040101

• Anidulafungin.

  Drugs 20040101

• In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.

  Revista iberoamericana de micologia 20031201

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20031101

• Anidulafungin Vicuron.

  IDrugs : the investigational drugs journal 20031001

• The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy.

  Expert opinion on investigational drugs 20030801

• Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. Results from a six-year study (1996-2001).

  Diagnostic microbiology and infectious disease 20030801

• New antifungal agents.

  Dermatologic clinics 20030701

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20030601

• In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp.

  Diagnostic microbiology and infectious disease 20030201

• Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method.

  The Journal of antimicrobial chemotherapy 20030101

• Anidulafungin: ECB, LY 303366, V-echinocandin, VEC, VER 002, VER-02.

  Drugs in R&D 20030101

• Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods.

  Diagnostic microbiology and infectious disease 20020501

• Clinical efficacy of echinocandin antifungals.

  Current opinion in infectious diseases 20011201

• The echinocandins, first novel class of antifungals in two decades: will they live up to their promise?

  International journal of clinical practice 20011101

• Clinical microbiology and infectious diseases. Management of fungal infections.

  IDrugs : the investigational drugs journal 20010701

• Hitting a new target with echinocandins. Why chase something else?

  Current opinion in investigational drugs (London, England : 2000) 20010401

• Update on antifungals targeted to the cell wall: focus on beta-1,3-glucan synthase inhibitors.

  Expert opinion on investigational drugs 20010201

• Regional-dependent intestinal absorption and meal composition effects on systemic availability of LY303366, a lipopeptide antifungal agent, in dogs.

  Journal of pharmaceutical sciences 20010101

• In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species.

  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20010101

• Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis.

  Antimicrobial agents and chemotherapy 20001201

• Drug interaction studies of a glucan synthase inhibitor (LY 303366) and a chitin synthase inhibitor (Nikkomycin Z) for inhibition and killing of fungal pathogens.

  Antimicrobial agents and chemotherapy 20000901

• Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B.

  The Journal of antimicrobial chemotherapy 20000901

• In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients.

  The Journal of antimicrobial chemotherapy 19991101

• Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits.

  Antimicrobial agents and chemotherapy 19981101

• Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.

  Journal of clinical microbiology 19981001

• In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp.

  Antimicrobial agents and chemotherapy 19981001

• Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis.

  Antimicrobial agents and chemotherapy 19980401

• The synthesis and antifungal activity of nitrogen containing hemiaminal ethers of LY303366.

  The Journal of antibiotics 19980201

• In vitro kill curves of a new semisynthetic echinocandin, LY-303366, against fluconazole-sensitive and -resistant Candida species.

  Antimicrobial agents and chemotherapy 19971101

• Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans.

  Antimicrobial agents and chemotherapy 19970901

• In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species.

  Antimicrobial agents and chemotherapy 19970401

• Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo.

  Antimicrobial agents and chemotherapy 19960801